ascopubs.org

Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use

Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer Purpose: To prospectively evaluate the ...
Nature

Positron Emission Tomography in Colorectal Cancer Detection

Positron emission tomography (PET) has emerged as an indispensable tool in oncological imaging, offering a non‐invasive approach to detect metabolic changes associated with colorectal tumours. Using ...
Cancer Therapy Advisor

Favorable Outcomes Seen With PSMA PET/CT-Guided Salvage Radiotherapy After Radical Prostatectomy

Whole-pelvis RT linked to improved PFS for patients with prostate cancer staged TrN0M0, while ADT linked to improved PFS in patients staged N1/M1 ...
ascopubs.org

Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer

Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer Initial FES uptake ...

Blue Earth Diagnostics to Highlight New POSLUMA® (Flotufolastat F 18) Study Results in Prostate Cancer at the 2026 ASCO Genitourinary Symposium (ASCO GU)

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced that ...
Taiwan News

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

At a per-patient level, 68 Ga-PSMA-11 identified 36% (18/50) of trial participants as having a positive scan, while 64 Cu-SAR-bisPSMA next-day imaging detected prostate cancer in 78% (39/50) of cases.